DOCSLIB.ORG

Investigating the Molecular Pathology of Dupuytren's Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Investigating the Molecular Pathology of Dupuytren's Disease The University of Notre Dame Australia ResearchOnline@ND Theses 2018 Investigating the molecular pathology of Dupuytren’s disease Robert Pearce The University of Notre Dame Australia Follow this and additional works at: https://researchonline.nd.edu.au/theses Part of the Medicine and Health Sciences Commons COMMONWEALTH OF AUSTRALIA Copyright Regulations 1969 WARNING The material in this communication may be subject to copyright under the Act. Any further copying or communication of this material by you may be the subject of copyright protection under the Act. Do not remove this notice. Publication Details Pearce, R. (2018). Investigating the molecular pathology of Dupuytren’s disease (Doctor of Philosophy (College of Medicine)). University of Notre Dame Australia. https://researchonline.nd.edu.au/theses/209 This dissertation/thesis is brought to you by ResearchOnline@ND. It has been accepted for inclusion in Theses by an authorized administrator of ResearchOnline@ND. For more information, please contact [email protected]. Investigating the Molecular Pathology of Dupuytren’s Disease Investigation of the Molecular Pathology of Dupuytren’s Disease Robert Pearce FRACS This thesis is presented for the degree of Doctor of Philosophy School of Medicine University of Notre Dame Australia (Fremantle) 2018 1 Contents Investigation of the Molecular Pathology of Dupuytren’s Disease ............................................................... 1 ABSTRACT .................................................................................................................................................. 7 ACKNOWLEDGEMENTS ........................................................................................................................ 10 CHAPTER 1 .............................................................................................................................................. 11 1.1 An overview of Dupuytren’s disease ................................................................................................ 11 1.2 Current clinical management of Dupuytren’s disease ....................................................................... 13 1.2.1 Prevention .................................................................................................................................. 13 1.3 Surgery to treat Dupuytren’s disease ................................................................................................. 13 1.3.1 Limited or partial fasciectomy.................................................................................................... 14 1.3.2 Dermofasciectomy ..................................................................................................................... 14 1.3.3 Z-Plasty repair ............................................................................................................................ 15 1.3.4 Amputation ................................................................................................................................. 15 1.3.5Percutaneous division of fibrous cords ........................................................................................ 16 1.4 Non-surgical treatment of Dupuytren’s disease ................................................................................ 16 1.4.1 Physical manipulation of Dupuytren’s contracture .................................................................... 16 1.4.2 Irradiation ................................................................................................................................... 17 1.4.3 Extracorporeal shockwave therapy ............................................................................................. 17 1.5 Pharmacological treatments of Dupuytren’s disease ......................................................................... 17 1.5.1 Intralesional steroid injection ..................................................................................................... 18 1.5.2 Intralesional collagenase injection ............................................................................................. 18 1.5.3 Intralesional gamma-interferon .................................................................................................. 18 1.6 Summary ........................................................................................................................................... 19 1.7 The Epidemiology of Dupuytren’s disease ....................................................................................... 20 1.7.1 Epidemiological evidence for a genetic component to Dupuytren’s disease. ............................. 21 1.8 The Molecular and cellular pathology of Dupuytren’s disease ......................................................... 22 1.8.1 The role of myofibroblasts in Dupuytren’s disease .................................................................... 22 1.8.2 The role of the immune system in Dupuytren’s disease ............................................................. 25 1.8.3 A role for vascular and innervation changes in Dupuytren’s disease ......................................... 26 1.9 Evidence for candidate susceptibility genes in Dupuytren’s disease ................................................ 27 1.10 Summary ......................................................................................................................................... 31 Hypothesis ................................................................................................................................................... 32 Aims ............................................................................................................................................................ 32 CHAPTER 2 .............................................................................................................................................. 33 2.1 Introduction ....................................................................................................................................... 33 Investigating the Molecular Pathology of Dupuytren’s Disease 2.2 Methods ............................................................................................................................................. 35 2.2.1 Ethics Approval .......................................................................................................................... 35 2.2.2 Participants ................................................................................................................................. 35 2.2.3 Saliva collection for genomic DNA isolation ............................................................................. 35 2.2.4 DNA isolation protocol .............................................................................................................. 36 2.2.5 DNA quantitation ....................................................................................................................... 36 2.2.6 Whole exome sequencing (WES) ............................................................................................... 36 2.2.7 Linkage analysis ......................................................................................................................... 38 2.2.8 Variant confirmation and prioritization ...................................................................................... 38 2.3 Results ............................................................................................................................................... 38 2.3.1 Genes identified using the SOLiD platform ............................................................................... 38 2.3.2 Genes identified using the Ion Proton sequencing platform ....................................................... 42 2.3.4 Genes identified using the Illumina platform ............................................................................. 50 2.3.5 Summary .................................................................................................................................... 50 2.4 Discussion ......................................................................................................................................... 51 2.4.1 Non-synonymous variants identified by WES in a family with Dupuytren’s disease ................ 51 2.4.2 Genes involved in angiogenesis ................................................................................................. 54 2.4.3 Genes with roles in inflammatory processes .............................................................................. 54 2.4.4 Candidate genes with neural functions ....................................................................................... 55 2.4.5 The absence of genes identified in previous studies ................................................................... 56 2.4.6 The advantages of using WES to identify causative mutations .................................................. 57 2.4.7 Limitations of using the WES approach ..................................................................................... 58 2.5 Summary ........................................................................................................................................... 61 CHAPTER 3 ............................................................................................................................................... 63 3.1 Introduction ......................................................................................................................................
Load more

Recommended publications
  • Xio Is a Component of the Drosophila Sex Determination Pathway and RNA N6-Methyladenosine Methyltransferase Complex
    Xio is a component of the Drosophila sex determination pathway and RNA N6-methyladenosine methyltransferase complex Jian Guoa,b, Hong-Wen Tangc, Jing Lia,b, Norbert Perrimonc,d,1, and Dong Yana,1 aKey Laboratory of Insect Developmental and Evolutionary Biology, Chinese Academy of Sciences Center for Excellence in Molecular Plant Sciences, Shanghai Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, 200032 Shanghai, China; bUniversity of Chinese Academy of Sciences, 100049 Beijing, China; cDepartment of Genetics, Harvard Medical School, Boston, MA 02115; and dHoward Hughes Medical Institute, Harvard Medical School, Boston, MA 02115 Contributed by Norbert Perrimon, February 14, 2018 (sent for review December 6, 2017; reviewed by James W. Erickson and Helen Salz) N6-methyladenosine (m6A), the most abundant chemical modifica- reader YT521-B, are required for Drosophila sex determination 6 tion in eukaryotic mRNA, has been implicated in Drosophila sex and Sxl splicing regulation. Further, m A modification sites have determination by modifying Sex-lethal (Sxl) pre-mRNA and facili- been mapped to Sxl introns, thus facilitating Sxl pre-mRNA al- 6 tating its alternative splicing. Here, we identify a sex determina- ternative splicing. Importantly, m A methylation is required in CG7358 xio human dosage compensation by modifying the long noncoding tion gene, , and rename it according to its loss-of- 6 function female-to-male transformation phenotype. xio encodes RNA XIST,suggestingthatmA-mediated gene regulation is an ancient
    [Show full text]
  • Guillaume Dupuytren and His Contributions to Knowledge About Tumors Anne J
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Transactions of the Nebraska Academy of Sciences Nebraska Academy of Sciences and Affiliated Societies 1982 Guillaume Dupuytren And His Contributions To Knowledge About Tumors Anne J. Krush Johns Hopkins Hospital Follow this and additional works at: http://digitalcommons.unl.edu/tnas Krush, Anne J., "Guillaume Dupuytren And His Contributions To Knowledge About Tumors" (1982). Transactions of the Nebraska Academy of Sciences and Affiliated Societies. 497. http://digitalcommons.unl.edu/tnas/497 This Article is brought to you for free and open access by the Nebraska Academy of Sciences at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Transactions of the Nebraska Academy of Sciences and Affiliated Societies by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. 1982. Transactions a/the Nebraska Academy a/Sciences, X:67-69. GUILLAUME DUPUYTREN AND HIS CONTRmUTIONS TO KNOWLEDGE ABOUT TUMORS Anne J. Krush The Johns Hopkins Hospital 600 North Wolfe Street Baltimore, Maryland 21205 Guillaume Dupuytren was born in the village of Pierrebuffi~re, on gave the order, "You will be a surgeon!" Dupuytren was en­ 5 October 1777. Though his father was a lawyer and parliamentarian, rolled in the medical-surgical school of the Saint Alexis many of Dupuytren's other ancestors had been physicians, mostly sur­ Hospital in Limoges. However, his family was unwilling to geons. Guillaume entered the College of Magnac-Laval at age seven. support him; so he returned to Paris, received a meager schol­ From age 12 to 17 he attended the Marche School in Paris.
    [Show full text]
  • Evolutionary Genomics of a Plastic Life History Trait: Galaxias Maculatus Amphidromous and Resident Populations
    EVOLUTIONARY GENOMICS OF A PLASTIC LIFE HISTORY TRAIT: GALAXIAS MACULATUS AMPHIDROMOUS AND RESIDENT POPULATIONS by María Lisette Delgado Aquije Submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy at Dalhousie University Halifax, Nova Scotia August 2021 Dalhousie University is located in Mi'kma'ki, the ancestral and unceded territory of the Mi'kmaq. We are all Treaty people. © Copyright by María Lisette Delgado Aquije, 2021 I dedicate this work to my parents, María and José, my brothers JR and Eduardo for their unconditional love and support and for always encouraging me to pursue my dreams, and to my grandparents Victoria, Estela, Jesús, and Pepe whose example of perseverance and hard work allowed me to reach this point. ii TABLE OF CONTENTS LIST OF TABLES ............................................................................................................ vii LIST OF FIGURES ........................................................................................................... ix ABSTRACT ...................................................................................................................... xii LIST OF ABBREVIATION USED ................................................................................ xiii ACKNOWLEDGMENTS ................................................................................................ xv CHAPTER 1. INTRODUCTION ....................................................................................... 1 1.1 Galaxias maculatus ..................................................................................................
    [Show full text]
  • Medical Students in England and France, 1815-1858
    FLORENT PALLUAULT D.E.A., archiviste paléographe MEDICAL STUDENTS IN ENGLAND AND FRANCE 1815-1858 A COMPARATIVE STUDY University of Oxford Faculty of Modern History - History of Science Thesis submitted for the degree of Doctor in Philosophy Trinity 2003 ACKNOWLEDGMENTS In the first instance, my most sincere gratitude goes to Dr Ruth Harris and Dr Margaret Pelling who have supervised this thesis. Despite my slow progress, they have supported my efforts and believed in my capacities to carry out this comparative study. I hope that, despite its defects, it will prove worthy of their trust. I would like to thank Louella Vaughan for providing an interesting eighteenth-century perspective on English medical education, sharing her ideas on my subject and removing some of my misconceptions. Similarly, I thank Christelle Rabier for her support and for our discussions regarding her forthcoming thesis on surgery in England and France. My thanks naturally go to the staff of the various establishments in which my research has taken me, and particularly to the librarians at the Wellcome Library for the History and Understanding of Medicine in London, the librarians in the History of Science Room at the Bibliothèque nationale de France in Paris, and to Bernadette Molitor and Henry Ferreira-Lopes at the Bibliothèque Inter-Universitaire de Médecine in Paris. I am grateful to Patricia Gillet from the Association d’entraide des Anciens élèves de l’École des Chartes for the financial support that the Association has given me and to Wes Cordeau at Texas Supreme Mortgage, Inc. for the scholarship that his company awarded me.
    [Show full text]
  • Table SI. Genes Upregulated ≥ 2-Fold by MIH 2.4Bl Treatment Affymetrix ID
    Table SI. Genes upregulated 2-fold by MIH 2.4Bl treatment Fold UniGene ID Description Affymetrix ID Entrez Gene Change 1558048_x_at 28.84 Hs.551290 231597_x_at 17.02 Hs.720692 238825_at 10.19 93953 Hs.135167 acidic repeat containing (ACRC) 203821_at 9.82 1839 Hs.799 heparin binding EGF like growth factor (HBEGF) 1559509_at 9.41 Hs.656636 202957_at 9.06 3059 Hs.14601 hematopoietic cell-specific Lyn substrate 1 (HCLS1) 202388_at 8.11 5997 Hs.78944 regulator of G-protein signaling 2 (RGS2) 213649_at 7.9 6432 Hs.309090 serine and arginine rich splicing factor 7 (SRSF7) 228262_at 7.83 256714 Hs.127951 MAP7 domain containing 2 (MAP7D2) 38037_at 7.75 1839 Hs.799 heparin binding EGF like growth factor (HBEGF) 224549_x_at 7.6 202672_s_at 7.53 467 Hs.460 activating transcription factor 3 (ATF3) 243581_at 6.94 Hs.659284 239203_at 6.9 286006 Hs.396189 leucine rich single-pass membrane protein 1 (LSMEM1) 210800_at 6.7 1678 translocase of inner mitochondrial membrane 8 homolog A (yeast) (TIMM8A) 238956_at 6.48 1943 Hs.741510 ephrin A2 (EFNA2) 242918_at 6.22 4678 Hs.319334 nuclear autoantigenic sperm protein (NASP) 224254_x_at 6.06 243509_at 6 236832_at 5.89 221442 Hs.374076 adenylate cyclase 10, soluble pseudogene 1 (ADCY10P1) 234562_x_at 5.89 Hs.675414 214093_s_at 5.88 8880 Hs.567380; far upstream element binding protein 1 (FUBP1) Hs.707742 223774_at 5.59 677825 Hs.632377 small nucleolar RNA, H/ACA box 44 (SNORA44) 234723_x_at 5.48 Hs.677287 226419_s_at 5.41 6426 Hs.710026; serine and arginine rich splicing factor 1 (SRSF1) Hs.744140 228967_at 5.37
    [Show full text]
  • ACTL8 (C-18): Sc-137276
    SAN TA C RUZ BI OTEC HNOL OG Y, INC . ACTL8 (C-18): sc-137276 BACKGROUND PRODUCT ACTL8 (actin-like protein 8), aslo known as CT57 (cancer/testis antigen 57), Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide is a member of the ARP family of actin-related proteins that contain an actin and 0.1% gelatin. fold and are involved in spindle orientation, nuclear migration and chromatin Blocking peptide available for competition studies, sc-137276 P, (100 µg remodeling events. Localized to the cytoplasm and expressed in the testis peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA). and pancreas, ACTL8 is 366 amino acids in length and is encoded by a gene that maps to human chromosome 1, which spans 260 million base pairs, APPLICATIONS contains over 3,000 genes and comprises nearly 8% of the human genome. Chromosome 1 houses a large number of disease-associated genes, including ACTL8 (C-18) is recommended for detection of ACTL8 of human origin those that are involved in familial adenomatous polyposis, Stickler syndrome, by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), Parkinson’s disease, Gaucher disease, schizophrenia and Usher syndrome. immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell Aberrations in chromosome 1 are found in a variety of cancers, including lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50- head and neck cancer, malignant melanoma and multiple myeloma. 1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30- 1:3000); non cross-reactive with ACTL7A or ACTL7B.
    [Show full text]
  • Mutational Landscape Differences Between Young-Onset and Older-Onset Breast Cancer Patients Nicole E
    Mealey et al. BMC Cancer (2020) 20:212 https://doi.org/10.1186/s12885-020-6684-z RESEARCH ARTICLE Open Access Mutational landscape differences between young-onset and older-onset breast cancer patients Nicole E. Mealey1 , Dylan E. O’Sullivan2 , Joy Pader3 , Yibing Ruan3 , Edwin Wang4 , May Lynn Quan1,5,6 and Darren R. Brenner1,3,5* Abstract Background: The incidence of breast cancer among young women (aged ≤40 years) has increased in North America and Europe. Fewer than 10% of cases among young women are attributable to inherited BRCA1 or BRCA2 mutations, suggesting an important role for somatic mutations. This study investigated genomic differences between young- and older-onset breast tumours. Methods: In this study we characterized the mutational landscape of 89 young-onset breast tumours (≤40 years) and examined differences with 949 older-onset tumours (> 40 years) using data from The Cancer Genome Atlas. We examined mutated genes, mutational load, and types of mutations. We used complementary R packages “deconstructSigs” and “SomaticSignatures” to extract mutational signatures. A recursively partitioned mixture model was used to identify whether combinations of mutational signatures were related to age of onset. Results: Older patients had a higher proportion of mutations in PIK3CA, CDH1, and MAP3K1 genes, while young- onset patients had a higher proportion of mutations in GATA3 and CTNNB1. Mutational load was lower for young- onset tumours, and a higher proportion of these mutations were C > A mutations, but a lower proportion were C > T mutations compared to older-onset tumours. The most common mutational signatures identified in both age groups were signatures 1 and 3 from the COSMIC database.
    [Show full text]
  • Scalable Phylogenetic Profiling Using Minhash Uncovers Likely Eukaryotic Sexual Reproduction Genes
    bioRxiv preprint doi: https://doi.org/10.1101/852491; this version posted November 22, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Scalable Phylogenetic Profiling using MinHash Uncovers Likely Eukaryotic Sexual Reproduction Genes 1,2,3,* 1,2,3 4,5 1,2,3,6,7,* David Moi ​ ,​ Laurent Kilchoer ,​ Pablo S. Aguilar ​ and Christophe Dessimoz ​ ​ ​ ​ 1 2 Department​ of Computational Biology, University of Lausanne, Switzerland; Center​ for Integrative Genomics, ​ 3 4 University of Lausanne, Switzerland; SIB​ Swiss Institute of Bioinformatics, Lausanne, Switzerland; Instituto​ de ​ ​ 5 Investigaciones Biotecnologicas (IIBIO), Universidad Nacional de San Martín Buenos Aires, Argentina; Instituto​ de ​ 6 Fisiología, Biología Molecular y Neurociencias (IFIBYNE-CONICET), Department​ of Genetics, Evolution, and ​ 7 Environment, University College London, UK; Department​ of Computer Science, University College London, UK. ​ *Corresponding authors: [email protected] and [email protected] Abstract Phylogenetic profiling is a computational method to predict genes involved in the same biological process by identifying protein families which tend to be jointly lost or retained across the tree of life. Phylogenetic profiling has customarily been more widely used with prokaryotes than eukaryotes, because the method is thought to require many diverse genomes. There are now many eukaryotic genomes available, but these are considerably larger, and typical phylogenetic profiling methods require quadratic time or worse in the number of genes. We introduce a fast, scalable phylogenetic profiling approach entitled HogProf, which leverages hierarchical orthologous groups for the construction of large profiles and locality-sensitive hashing for efficient retrieval of similar profiles.
    [Show full text]
  • Adaptive History of the Chimpanzee Subspecies in the Genomic Era
    Adaptive History of the Chimpanzee Subspecies in the Genomic Era Jessica Nye TESI DOCTORAL UPF 2018 Directors de la Tesi Jaume Bertranpetit i Hafid Laayouni CIÈNCIES EXPERIMENTALS I DE LA SALUT ii Acknowledgements I would like to thank my advisors Dr. Jaume Bertranpetit and Dr. Hafid Laayouni for guiding me during my doctoral research. I would like to thank my family and friends for supporting me during my many years of education. To my fellow lab mates, I am grateful for the theoretical discussions we had over the last four years. This work was supported by FI Agaur grant FI-DGR 2015. iii iv Abstract Chimpanzees are our closest living genetic cousins. The species consists of four subspecies, each with a unique demographic history. In order to better understand their species, a detailed map of signatures of selection will highlight important genetic differences between the four subspecies. Here, we interrogate the genome using 15 tests of selection. We simulate neutral and selective scenarios taking their unique demographic history into account in the model. We combine all these elements using a machine learning approach to highlight regions of interest in each subspecies. We specifically investigate the regions of the genome that have been selected after introgression with bonobo. We investigate the haplotype changes that have occurred since the divergence with humans in a few specially selected genes. From this, we find that the evolutionary history of each of the four subspecies is unique. That subtle differences in their demographic history and environment have greatly shaped their genetic diversity. In general, we observe signatures in selection in phenotypes involving immunity, muscle function, reproduction, and DNA repair.
    [Show full text]
  • Analysis of Diet-Induced Differential Methylation, Expression, And
    www.nature.com/scientificreports OPEN Analysis of diet-induced diferential methylation, expression, and interactions of lncRNA and protein- Received: 2 March 2018 Accepted: 29 June 2018 coding genes in mouse liver Published: xx xx xxxx Jose P. Silva1 & Derek van Booven2 Long non-coding RNAs (lncRNAs) regulate expression of protein-coding genes in cis through chromatin modifcations including DNA methylation. Here we interrogated whether lncRNA genes may regulate transcription and methylation of their fanking or overlapping protein-coding genes in livers of mice exposed to a 12-week cholesterol-rich Western-style high fat diet (HFD) relative to a standard diet (STD). Deconvolution analysis of cell type-specifc marker gene expression suggested similar hepatic cell type composition in HFD and STD livers. RNA-seq and validation by nCounter technology revealed diferential expression of 14 lncRNA genes and 395 protein-coding genes enriched for functions in steroid/cholesterol synthesis, fatty acid metabolism, lipid localization, and circadian rhythm. While lncRNA and protein-coding genes were co-expressed in 53 lncRNA/protein-coding gene pairs, both were diferentially expressed only in 4 lncRNA/protein-coding gene pairs, none of which included protein- coding genes in overrepresented pathways. Furthermore, 5-methylcytosine DNA immunoprecipitation sequencing and targeted bisulfte sequencing revealed no diferential DNA methylation of genes in overrepresented pathways. These results suggest lncRNA/protein-coding gene interactions in cis play a minor role mediating hepatic expression of lipid metabolism/localization and circadian clock genes in response to chronic HFD feeding. More than 70% of the mammalian genome is transcribed as non-coding RNA (ncRNA) while only 1–2% of the mammalian genome is transcribed as protein-coding RNA1–3.
    [Show full text]
  • Cellular and Molecular Aspects of the Response of the Testis to Nutrition In
    Cellular and molecular aspects of the response of the testis to nutrition in sexually mature sheep Yongjuan Guan 21004548 This thesis is presented for the degree of Doctor of Philosophy of The University of Western Australia School of Animal Biology Institute of Agriculture March 2015 Declaration Declaration The work presented in this thesis is original work of the author, and none of the material in this thesis has been submitted either in full, or part, for a degree at this university or any other universities or institutions before. The experimental designs and manuscript preparation were carried out by myself after discussion with my supervisors Prof Graeme Martin, A/Prof Irek Malecki and Dr Penny Hawken. Yongjuan Guan March 2015 1 Contents Contents Summary ....................................................................................................................................... 4 Acknowledgements ....................................................................................................................... 8 Publications ................................................................................................................................. 10 Chapter 1: General Introduction ................................................................................................. 12 Chapter 2: Literature Review ...................................................................................................... 16 2.1 Male reproduction ............................................................................................................
    [Show full text]
  • Novel Gene Discovery in Primary Ciliary Dyskinesia
    Novel Gene Discovery in Primary Ciliary Dyskinesia Mahmoud Raafat Fassad Genetics and Genomic Medicine Programme Great Ormond Street Institute of Child Health University College London A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy University College London 1 Declaration I, Mahmoud Raafat Fassad, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. 2 Abstract Primary Ciliary Dyskinesia (PCD) is one of the ‘ciliopathies’, genetic disorders affecting either cilia structure or function. PCD is a rare recessive disease caused by defective motile cilia. Affected individuals manifest with neonatal respiratory distress, chronic wet cough, upper respiratory tract problems, progressive lung disease resulting in bronchiectasis, laterality problems including heart defects and adult infertility. Early diagnosis and management are essential for better respiratory disease prognosis. PCD is a highly genetically heterogeneous disorder with causal mutations identified in 36 genes that account for the disease in about 70% of PCD cases, suggesting that additional genes remain to be discovered. Targeted next generation sequencing was used for genetic screening of a cohort of patients with confirmed or suggestive PCD diagnosis. The use of multi-gene panel sequencing yielded a high diagnostic output (> 70%) with mutations identified in known PCD genes. Over half of these mutations were novel alleles, expanding the mutation spectrum in PCD genes. The inclusion of patients from various ethnic backgrounds revealed a striking impact of ethnicity on the composition of disease alleles uncovering a significant genetic stratification of PCD in different populations.
    [Show full text]